Direkt zum Inhalt
Merck

Establishment and phenotyping of disease model cells created by cell-resealing technique.

Scientific reports (2017-11-11)
Fumi Kano, Yoshiyuki Noguchi, Masayuki Murata
ZUSAMMENFASSUNG

Cell-based assays are growing in importance for screening drugs and investigating their mechanisms of action. Most of the assays use so-called "normal" cell strain because it is difficult to produce cell lines in which the disease conditions are reproduced. In this study, we used a cell-resealing technique, which reversibly permeabilizes the plasma membrane, to develop diabetic (Db) model hepatocytes into which cytosol from diabetic mouse liver had been introduced. Db model hepatocytes showed several disease-specific phenotypes, namely disturbance of insulin-induced repression of gluconeogenic gene expression and glucose secretion. Quantitative image analysis and principal component analysis revealed that the ratio of phosphorylated Akt (pAkt) to Akt was the best index to describe the difference between wild-type and Db model hepatocytes. By performing image-based drug screening, we found pioglitazone, a PPARγ agonist, increased the pAkt/Akt ratio, which in turn ameliorated the insulin-induced transcriptional repression of the gluconeogenic gene phosphoenolpyruvate carboxykinase 1. The disease-specific model cells coupled with image-based quantitative analysis should be useful for drug development, enabling the reconstitution of disease conditions at the cellular level and the discovery of disease-specific markers.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Pioglitazone
Sigma-Aldrich
Anti-Akt/PKB-Antikörper, PH-Domäne, Klon SKB1, clone SKB1, Upstate®, from mouse